Oct 16, 2024 Press Release for Alnylam
6 days ago · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking ...
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in …
4 days ago · Shares of the company gained 4.6% in response to the encouraging news. Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary ...
Alnylam Pharma Submits Type II Variation To European Medicines …
5 days ago · (RTTNews) - Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic in development for ...
Alnylam to Webcast Conference Call Discussing Third Quarter …
4 days ago · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ...
Press Releases - Alnylam Pharmaceuticals, Inc.
Aug 1, 2024 · Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Sep 29, 2024 Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society ...
Alnylam® Newsroom
Perspectives Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access a ... Perspectives 2023 Year in Review: CEO Yvonne Greenstreet Reflects on a Year of Substantial Growth an ... Visit our social channels to learn more about the innovative work we are doing at Alnylam. Copyright © 2024 Alnylam Pharmaceuticals, Inc.
Alnylam's drug cuts risk of death, heart issues in key study, shares ...
June 24 (Reuters) - Alnylam Pharmaceuticals (ALNY.O) said its drug vutrisiran reduced deaths and cardiovascular events by a third in a study involving patients with a rare heart disease, sending...
Articles | Alnylam® Newsroom
Aug 15, 2024 · April 26, 2024 Better Together: Alnylam and Organized Customer Health Systems Want to Improve Access and ... Alnylam's Head of Strategic Accounts discusses the rise of the Integrated Delivery Network and manufacturer relationship Read More ›
Alnylam Announces Receipt of Complete Response Letter from …
Oct 9, 2023 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation...
US biotech Alnylam hails positive trial results for heart disease drug
Jun 24, 2024 · Shares in Alnylam Pharmaceuticals jumped after the company said a drug to treat a rare form of heart disease met its goals in a late-stage trial, opening up the possibility of billions of dollars...